Introduction {#sec1_1}
============

Choriocarcinoma is a highly aggressive and vascular germ cell tumor that occurs mostly in men aged 20--39 years. It has a tendency to grow rapidly, with a high risk of tumor hemorrhage and hematogenous spread to various organs. It is uniquely chemosensitive and often curable, even in cases of advanced and metastatic disease. Approximately 10% of choriocarcinomas metastasize to the brain \[[@B1]\]. Due to its low incidence, the optimal treatment strategies of brain metastases of choriocarcinoma remain controversial \[[@B2], [@B3]\]. Although surgery, radiation, and chemotherapy remain the mainstays of the management of brain metastases, the prognosis remains poor.

Case Report {#sec1_2}
===========

A 33-year-old man with no significant medical history presented with incidentally detected multiple lung nodules on a chest X-ray (Fig. [1a](#F1){ref-type="fig"}). Computed tomography (CT) demonstrated numerous lobulated nodular densities throughout the bilateral lungs, along with a pelvic mass (Fig. [1b, c](#F1){ref-type="fig"}). Positron emission tomography (PET) revealed 2-deoxy-2-\[^18^F\]-fluoro-d-glucose uptake in the pulmonary nodules, pelvic mass and bones, and focal defects in the brain, which suggested brain metastases (Fig. [1d, e](#F1){ref-type="fig"}). He was scheduled to undergo pelvic tumor biopsy but was urgently hospitalized for his progressive headache and nausea. Laboratory examination revealed highly elevated serum lactate dehydrogenase, but no other findings suggested a specific type of malignancy (Table [1](#T1){ref-type="table"}). Physical examination showed a palpable mass and tenderness from the left groin to the lower abdomen and right homonymous hemianopsia. Brain magnetic resonance imaging (MRI) with contrast enhancement showed multiple metastases, especially a progressive enhancing lesion in the right cerebellum (Fig. [2a](#F2){ref-type="fig"}). He underwent emergency craniotomy for resection of the cerebellar lesion because of its rapid growth. Head CT on the following day displayed progressive acute parenchymal hemorrhage in the left occipital lobe tumor (Fig. [2b](#F2){ref-type="fig"}). He underwent a second craniotomy to control the intratumoral hemorrhage. Rapid pathological diagnosis of the cerebellar lesion showed a biphasic pattern of malignant epithelioid cells and intermixed multinucleated giant cells, which was highly suspicious of metastatic choriocarcinoma (Fig. [3](#F3){ref-type="fig"}).

He immediately received chemotherapy with bleomycin, etoposide, and cisplatin (BEP) after the detection of urinary human chronic gonadotropin (hCG). The size of the pelvic mass and pulmonary lesions decreased, and the β-hCG level decreased markedly to 490 ng/mL from 13,000 ng/mL after one cycle of BEP. However, brain MRI displayed an increase in the size and number of metastatic brain lesions. He underwent daily fractionated whole-brain radiotherapy (WBRT) (40 Gy in 10 fractions) concurrently with two cycles of BEP. Brain MRI after WBRT revealed a reduction in size of brain metastases. He completed 4 cycles of BEP with a favorable decrease in the β-hCG level and in the size of the pelvic mass as well as brain and pulmonary lesions. However, the β-hCG level was still higher than the normal range, and the pelvic and pulmonary lesions remained. He continued chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) with the aim of normalizing the β-hCG level and eliminating residual tumors. Because he could not tolerate joint and muscle pain and because of leg numbness caused directly by paclitaxel, he received etoposide, ifosfamide, and cisplatin (VIP) after 4 cycles of TIP. His β-hCG level finally normalized after 3 cycles of VIP, but the residual pelvic mass was more than 1 cm in diameter. It was resected and was found to have no viable cancer cells (Fig. 4). He has been followed up without treatment and has shown no disease recurrence or significant neurotoxicity.

Discussion {#sec1_3}
==========

Although most patients with advanced germ cell tumors can achieve long-term survival, patients with brain metastases have been considered to have poor prognoses \[[@B4]\]. Moreover, there is no clear consensus regarding the optimal therapeutic strategy for these patients \[[@B2], [@B3]\]. Some research groups advocate chemotherapy alone \[[@B5]\], multimodal treatment \[[@B6], [@B7], [@B8]\], or even topical treatment (surgery or radiotherapy) alone \[[@B9]\]. According to a recent large retrospective study, the general use of surgery and/or radiation in addition to chemotherapy was not recommended for germ cell tumor patients with brain metastasis, especially not for patients with low risk factors \[[@B10]\]. However, we suggest that additional radiation therapy and/or neurosurgery might be beneficial in particular clinical settings according to individual characteristics.

Metastases from choriocarcinoma are frequently hemorrhagic and can lead to serious morbidity \[[@B11]\]. Tumor hemorrhage is a major cause of morbidity, especially in patients with brain metastases \[[@B12]\]. Logothetis \[[@B13]\] described hemorrhagic events after chemotherapy at the site of metastases containing high-volume choriocarcinomatous elements, which was termed as "choriocarcinoma syndrome." Given the high mortality associated with tumor hemorrhage and the possibility of further hemorrhage induced by chemotherapy, surgical intervention should be considered a reliable option for preventing critical cerebral hemorrhage in brain metastasis from choriocarcinoma. In this case, spontaneous tumor hemorrhage was identified before induction of chemotherapy, and thus, the patient first underwent craniotomy.

There was an increase in the size and number of metastatic brain lesions after a cycle of BEP, in spite of shrinkage of other lesions. Due to the progressive multiple brain metastases observed after surgery and chemotherapy, additional WBRT was considered for controlling the brain lesions. Because lower dose intensity of BEP has been reported to result in poor prognosis, BEP should be administered without delay whenever possible \[[@B14]\]. In contrast, WBRT has a risk of late neurotoxicity, including progressive leukoencephalopathy, and concurrent treatment with cranial radiotherapy and some systemic chemotherapy can increase the possibility of neurotoxicity \[[@B5], [@B10]\]. However, in a recent study, an increase in neurotoxicity was not observed when etoposide and cisplatin were administered concurrently with cranial radiation \[[@B15]\]. Although the concurrent use of bleomycin and cerebral radiotherapy has not been previously reported to our knowledge, we thought that it should be relatively safe because of the infrequent neurotoxicity associated with bleomycin use. Actually, the patient has not experienced any late neurotoxicity for at least 1 year.

In summary, multimodal treatment, including two craniotomies and chemotherapy concurrent with WBRT, can result in good control of lesions of the brain and other sites. However, further studies are needed to confirm the efficacy and safety of this multimodal treatment.
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![Chest X-ray revealing multiple lung nodules (**a**). Computed tomography revealing bilateral lung nodules (**b**) and a pelvic mass (**c**). Positron emission tomography revealing 2-deoxy-2-\[^18^F\]-fluoro-d-glucose accumulation in lung nodules, pelvic mass, bones (**d**), and focal defects in the brain (**e**).](cro-0012-0928-g01){#F1}

![Brain magnetic resonance imaging showing a contrast-enhancing lesion in the right cerebellum (**a**). Brain computed tomography on the day following the first craniotomy showing acute intratumoral hemorrhage in the left occipital lobe (**b**). Gross appearance of hemorrhagic and necrotic cerebellar masses (**c**). Hematoxylin-and-eosin-stained section of the tumor showing biphasic pattern of malignant epithelioid cells and intermixed multinucleated giant cells (**d**).](cro-0012-0928-g02){#F2}

![Clinical course: *y*-axis showing the β-human chorionic gonadotropin (β-hCG) level. The patient underwent whole-brain radiotherapy (WBRT) concurrently with 2 cycles of bleomycin, etoposide, and cisplatin (BEP). He continued chemotherapy with paclitaxel, ifosfamide, and cisplatin (TIP) and etoposide, ifosfamide, and cisplatin (VIP).](cro-0012-0928-g03){#F3}

###### 

Laboratory data on admission

  ------------- -------------- ------- ---------------- ------- -------
  *CBC*                                Na               139     mEq/L
  WBC           12.8 × 10^3^   /µL     Cl               103     mEq/L
  HGB           15.0           g/dL    K                4.1     mEq/L
  PLT           27.4 × 10^4^   /µL     Ca               9.0     mg/dL
                                       Glu              109     mg/dL
  *Chemistry*                          CRP              1.72    mg/dL
  AST           46             IU/L                             
  ALT           94             IU/L    *Tumor marker*           
  LDH           1,692          IU/L    CEA              1.4     ng/mL
  ALP           383            IU/L    CA19-9           6.7     IU/L
  TP            6.4            g/dL    AFP              3.3     ng/mL
  Alb           3.6            g/dL    SCC              1.0     ng/mL
  BUN           12             mg/dL   ProGRP           26.8    pg/mL
  Cr            0.69           mg/dL   sIL2-R           1,000   IU/L
  UA            4.1            mg/dL                            
  ------------- -------------- ------- ---------------- ------- -------

CBC, complete blood count; WBC, white blood cell count; HGB, hemoglobin; PLT, platelet count; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; ALP, alkaline phosphatase; TP, total protein; Alb, albumin; BUN, urea nitrogen; Cr, creatinine; UA, uric acid; Na, sodium; Cl, chloride; K, potassium; Ca, calcium; Glu, glucose; CRP, C-reactive protein; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; AFP, alpha-fetoprotein; SCC, squamous cell carcinoma; ProGRP, pro-gastrin-releasing peptide; sIL2-R, soluble interleukin 2-receptor.
